Altimmune Inc (ALT)
7.20
+0.12
(+1.69%)
USD |
NASDAQ |
Apr 25, 16:00
7.16
-0.04
(-0.56%)
After-Hours: 20:00
Altimmune Accounts Receivable (Quarterly): 1.111M for Dec. 31, 2023
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 1.111M |
September 30, 2023 | 0.876M |
June 30, 2023 | 0.136M |
March 31, 2023 | 0.252M |
December 31, 2022 | 0.173M |
September 30, 2022 | 0.633M |
June 30, 2022 | 0.195M |
March 31, 2022 | 0.193M |
December 31, 2021 | 0.429M |
September 30, 2021 | 1.574M |
June 30, 2021 | 4.463M |
March 31, 2021 | 4.801M |
December 31, 2020 | 4.610M |
September 30, 2020 | 3.816M |
June 30, 2020 | 1.182M |
March 31, 2020 | 1.995M |
December 31, 2019 | 1.021M |
September 30, 2019 | 1.012M |
June 30, 2019 | 2.630M |
March 31, 2019 | 2.906M |
December 31, 2018 | 3.462M |
September 30, 2018 | 2.547M |
June 30, 2018 | 2.854M |
March 31, 2018 | 3.755M |
December 31, 2017 | 3.806M |
Date | Value |
---|---|
September 30, 2017 | 2.902M |
June 30, 2017 | 3.572M |
March 31, 2017 | 0.2419M |
December 31, 2016 | 0.383M |
September 30, 2016 | 0.6657M |
June 30, 2016 | 1.024M |
March 31, 2016 | 0.1703M |
December 31, 2015 | 0.512M |
September 30, 2015 | 0.00 |
June 30, 2015 | 0.3876M |
March 31, 2015 | 5.974M |
December 31, 2014 | 0.1107M |
September 30, 2014 | 0.00 |
June 30, 2014 | 0.00 |
March 31, 2014 | 0.00 |
December 31, 2013 | 1.427M |
September 30, 2013 | 0.00 |
June 30, 2013 | 1.540M |
March 31, 2013 | 1.866M |
December 31, 2012 | 2.433M |
September 30, 2012 | 1.606M |
June 30, 2012 | 3.445M |
March 31, 2012 | 1.146M |
December 31, 2011 | 4.424M |
September 30, 2011 | 4.040M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
0.136M
Minimum
Jun 2023
4.801M
Maximum
Mar 2021
1.637M
Average
1.021M
Median
Dec 2019
Accounts Receivable (Quarterly) Benchmarks
Eli Lilly and Co | 9.090B |
Amgen Inc | 7.268B |
Viking Therapeutics Inc | -- |
Precision BioSciences Inc | 0.901M |
Terns Pharmaceuticals Inc | -- |